Cancer – Page 5

A Rapid Clinical Digital Patient-derived Organoid to Guide Breast Cancer Treatment Decision

Post author:
Post published:May 7, 2026
Post category:

Translational Candidate The digital patient organoid (DPO) assay is a microfluidic miniature organoid technology that allows high-throughput drug testing. Area of Impact Our functional DPO assay will guide personalized therapy…

GlyTR2 CAR T cell translation: safe pan-cancer killing via velcro-like density-dependent targeting of cancer glycans

Post author:
Post published:May 7, 2026
Post category:

FM-IL2 CAR T cells for Pancreatic Cancer

Post author:
Post published:May 7, 2026
Post category:

Development of an off-the-shelf iPSC derived CAR T cell therapy for the treatment of solid tumors

Post author:
Post published:May 7, 2026
Post category:

A Novel Gene Therapy to Target Glioblastoma via Custom-Engineered Adenovirus-Associated Viral Vectors

Post author:
Post published:May 7, 2026
Post category:

A novel non-genotoxic antibody conditioning therapeutic to expand access to and safety of HSCT and CD34+ gene therapies

Post author:
Post published:May 7, 2026
Post category:

Targeting pancreatic cancer with Allogeneic Off-the-Shelf PSCA-CAR NK cells

Post author:
Post published:May 7, 2026
Post category:

Translational Candidate PSCA-CAR_sIL15 NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells Area of Impact patients with metastatic pancreatic cancer or other cancers that also highly express PSCA…

Combating Ovarian Cancer with Stem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy

Post author:
Post published:May 7, 2026
Post category:

Translational Candidate stem cell-based off-the-shelf CAR-NKT cells Area of Impact ovarian cancer (OC) Mechanism of Action The proposed cell therapy candidate, AlloMCAR-NKT cells, can directly kill OC tumor cells through…

Hypoimmunogenic iPSC-derived TCR-NK cells for oncology

Post author:
Post published:May 7, 2026
Post category:

Translational Candidate iPSC-derived NY-ESO-1 TCR/IL-15 NK cells Area of Impact NK drug product homogeneity and engraftment/response durability will be improved by this hypoimmunogenic iPSC-TCR-NK therapy in cancer patients Mechanism of…

Development of an AAV gene therapy immunotherapy for the treatment of glioblastoma

Post author:
Post published:May 7, 2026
Post category:

Translational Candidate SRN-101, an experimental AAV gene therapy for treating glioblastoma Area of Impact Cancer - solid tumors Mechanism of Action Following delivery with an AAV, engineered cytokines are expressed…